SydneyAnd the 5 September 2022 /PRNewswire/ – Health analytics leader Prospection has announced a unique global data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. (MDV) to accelerate healthcare analytics globally.
The agreement, which covers the world’s second largest drug market, will provide global pharmaceutical companies and researchers access to comprehensive and longitudinal data covering more than 40 million people in the world. Japan In more than 470 hospitals.
By combining predictive analytics, machine learning, and real-world healthcare data, Prospection’s agreement with MDV will provide pharmaceutical companies around the world with unique access to patient and drug diagnostic data from hospitals around the world. Japanand unlock the potential to evaluate an unlimited number of treatment programs in the region.
The agreement also provides access to patient history and county-level data, allowing analysis of disease progression and disease outcome and mapping of disease cycles to provide evidence of areas where development can meet unmet needs. When distilled further, this creates an opportunity to evaluate patient data at the regional level to find geographical areas where patients or health centers need additional support for specific diseases and conditions.
prospecting access to Japan More comprehensive medical data sets are a milestone for the company. Prospection currently provides real-time access to longitudinal patient data across 15 regions worldwide including AustraliaAnd the New ZealandAnd the JapanAnd the South KoreaAnd the TaiwanAnd the United States of America and the United Kingdom. The company’s latest announcement with Medical Data Vision will build on this work, providing access to one of the Prospection sites Japan The largest healthcare databases.
Global healthcare benefits
according to academic research,* Only 60% of healthcare is in line with evidence-based guidelines, with the remaining 40% categorized as wasted, of low value or harmful in some cases. By analyzing the longitudinal histories of hundreds of millions of patients, the Prospection database can help the healthcare industry evaluate the use, value, and outcomes of treatments to find 40% and determine how to improve them.
By enabling pharmaceutical companies and health researchers around the world to better understand the full cycle of health conditions and disease journeys, this data will allow global life sciences companies to:
1. Gather patient and market insights
By analyzing specific health conditions and patient journeys, pharmaceutical companies can determine where, when and how to invest their resources and how to position their brand in the Japanese pharmaceutical market while forecasting the supply chain and developing models for market access.
2. Searching for patients and developing tactical plans
Life sciences companies can use the data to geographically determine where patients with the greatest disease burden in their treatment offerings are treated. The companies can then deploy their regional field teams with the right messages to support clinicians to help those patients who need treatment.
3. Data dissemination
Access to one of Japan’s most comprehensive medical data sets also creates an opportunity to add a body of clinical evidence for health conditions to help lead to a better understanding of specific diseases.
4. Get decision support
Provide health care providers with stimulating events to aid in targeted education when it is most needed, and support the clinician at the point of care with the patient.
Kaoru SatoCountry Manager, Exploration, JapanHe said:
“We are pleased to announce our latest agreement with Medical Data Vision. This partnership demonstrates a shared commitment to improving patient outcomes and represents a significant milestone in Prospection’s mission to deliver true societal benefits to patients around the world.
“As one of the largest pharmaceutical markets in the world, Japan It has incredibly rich data sets. Working with Medical Data Vision gives us access to a data set of nearly 40 million patients, creating a unique opportunity to use advanced analytical tools to accelerate precision medicine to enable the right patient to receive the right treatment at the right time in their journey.
“The results of this partnership will play a key role in understanding the full cycle of patients’ health conditions and disease journeys in areas including immuno-oncology, immune disorders, cardiovascular disease, and metabolism, enabling researchers and pharmaceutical companies globally to better understand different patient characteristics, treatments, and related outcomes.”
Eric ChungCEO and Co-Founder of Prospection said:
“We are very excited to be working with MDV on their latest data access agreement. Combining MDV’s large and comprehensive data set with global access to forecasts and extensive experience working with data sets around the world will not only allow MNC drug companies to work with patient data from JapanBut it will also open up a broader understanding of different health conditions around the world. This agreement brings us one step closer to improving precision medicine to find 40% of patients who can be improved.”
prospecting is a leading health data analytics technology company. We are on a mission to advance precision medicine through factual evidence, with the goal of putting the right patient into the right treatment at the right time. By applying advanced ML algorithms to real-world data, we reveal insights into the health and treatment journey by analyzing longitudinal data from hundreds of millions of patients to learn how drug treatments are used after a clinical trial. Providing realistic, actionable evidence that enables better outcomes for patients around the world.
Exploration is guided by certified experts and innovative leaders in their respective fields. Globally, we work with more than 15 large health data sets (claims, electronic medical records, commercial records), and apply our expertise to examine health patterns. Working with government and researchers down to our core client base in the pharmaceutical/biopharmaceutical industry, we have provided insights across more than 90 therapeutic indications. Including rare and complex diseases such as tumors, immuno-oncology, virology, metabolic diseases, respiratory and cardiovascular diseases. Prospection is backed by investors including Ellerston, Horizons Ventures and Main Sequence, and commercially with CRO Novotech.
LinkedIn Company: prospect-au https://www.linkedin.com/company/prospection-au/
Dealing with Twitter:_Prospection https://twitter.com/_Prospection
Facebook Prospection Global: https://www.facebook.com/ProspectionGlobal/
About Medical Data Vision (MDV)
MDV is an accumulation of data processed anonymously with secondary use permission from medical institutions. The actual number of patients in the acute phase centered “hospital data” is 40.42 million (counted at the end of July 2022). In addition, by retaining data from the Health Insurance Association, data on recovery and chronic period were improved, as well as information by hospital / clinic, it became possible to track information about transfer destinations. Health insurance data amounted to 7.84 million people (the same).